We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
A new world is possible. Let's not go back to what wasn't working anyway.
Add this topic to your myFT Digest for news straight to your inbox
Stable funding for work on less glamorous diseases would make the system fairer and more resilient
Personalised cancer treatments are among those being developed using a technology once distrusted by big pharma
US pharma group seeks authorisation for first drug of its kind after ‘remarkable’ clinical trial
French group says it is too late to market jab and is working on another with GSK using different technique
Scientists seek breakthrough in effort to ease virus symptoms and speed up recovery times
Without decisive action, there could be 10m deaths a year due to AMR by 2050 — and a cumulative cost to the global economy of $100tn
A once-a-month injection could replace patients’ daily cocktail of drugs
Exscientia’s drug development programme secures funding from Gates Foundation
Studies suggest stronger immune response than its mRNA rival and it wanes more slowly
US drugmaker to buy all shares of Trillium Therapeutics as part of investment in blood cancers
Clinical trial shows drug significantly reduces development of symptomatic Covid compared with placebo
It wants to monetise the trade in iboga, which is reputed to help people kick drug addictions
Pharma group blames ‘misinformation’ for overshadowing approval of therapy
UK drugmaker seeks to unlock £400m of private investment for site in Stevenage
Hong Kong-based platform has 16 programmes in development including potential cancer and Covid treatments
Moves to ease market access for generic drugmakers are gaining momentum
Eisai says framework for testing and treatment urgently needed in response to ‘secret pandemic’
Phase 3 stage shows drug not significantly more effective than placebo
Emer Cooke stressed that depending too heavily on a single shot could be self-defeating
UK pharma group will pay iTeos Therapeutics up to $2.1bn to collaborate on a tumour drug
Sum amassed by Flagship Pioneering is among largest in pharmaceutical industry
US biotech says pandemic has helped it accelerate development of new class of drugs
US approval of the Biogen treatment has given patients hope. But some experts worry expectations have been raised too high
Latecomers hope size, price or novel technology mean they can still play an important role in the pandemic
FDA signs off on first new treatment for disease in almost 20 years despite controversy over efficacy
International Edition
